San Diego is the third-largest biotech hub in the United States, behind Boston/Cambridge and the Bay Area. With more than 1,400 life sciences companies clustered between Torrey Pines, Sorrento Valley, and UTC, the competition for clinical, commercial, and capital attention is fierce.
For pre-commercial and early-commercial biotech companies, hiring a full-time CMO at $350K+ all-in is rarely the right first move. A fractional CRO (Chief Revenue Officer) delivers senior go-to-market leadership at a fraction of the cost — and ships revenue systems in weeks, not quarters.
What a fractional CRO actually owns in a biotech context
A biotech CRO is not a pharma sales VP. The remit covers the full revenue surface: positioning for partnering and licensing conversations, KOL and investor narrative, demand systems for diagnostics or tools companies, channel strategy for CDMOs and CROs selling into pharma, and the marketing-ops backbone that ties it together.
Why San Diego founders specifically benefit
The talent pool here is deep on R&D and clinical, but commercial leadership is thin compared to Boston. Founders who try to recruit a full-time CMO often wait six to nine months and pay a relocation premium. A San Diego-based fractional CRO is on the ground, in the Torrey Pines / Sorrento Valley corridor, and can be in your office the same week.
When to graduate from fractional to full-time
The honest answer: when revenue or pipeline justifies the headcount. For most Series A and Series B biotechs, that's 12 to 18 months after engaging a fractional CRO who has already built the system the future CMO will inherit.